Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Potential Utility of Event-Free Survival (EFS) As Surrogate Endpoint for Overall Survival (OS) in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) after Autologous Stem Cell Transplantation (ASCT): A Subgroup Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Randomized Phase III Trial

Shen Li, MD, Annette E Hay, Michael Crump, MD, Peter Anglin, MD FRCPC, MBA, Tara Baetz, Ralph Meyer, MDFRCPC, Armand Keating, MD, Sue Robinson, MD, Matthew Seftel, MRCP, MD MPH, FRCPC, Caterina Stelitano, Marina S Djurfeldt, MSc, Lois E. Shepherd, Bingshu E. Chen, Sarit Assouline, MD

Blood (2017) 130 (Supplement 1): 2015.

https://doi.org/10.1182/blood.V130.Suppl_1.2015.2015

Published: 2017

Journal Articles

Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Anca Prica, MD FRCP(C), Annette E Hay, Michael Crump, MD, Nicole Mittman, Lois E. Shepherd, Ralph Meyer, MDFRCPC, Kevin Imrie, MD, Nancy A. Risebrough, Marina S Djurfeldt, MSc, Bingshu E. Chen, Matthew Cheung, MD MS, FRCP

Blood (2017) 130 (Supplement 1): 4673.

https://doi.org/10.1182/blood.V130.Suppl_1.4673.4673

Published: 2017

Journal Articles

Comparison of Outcomes By Age of Patients with Limited Stage Hodgkin Lymphoma Treated with ABVD Alone; A Secondary Analysis of the Canadian Cancer Trial Group HD.6 Trial

Laura N Rodriguez-Romo, MD, Ralph Meyer, MDFRCPC, Joseph L Pater, MD, Jonathan Sussman, MD FRCPC, MSc, Siwei Zhang, MSc, Lui Hongbo, MSc, PhD, Jane N. Winter, MD, Te Vuong, MD, Walter Blahey, MD, Liam Mulroy, MD, Lois E. Shepherd, Marina S Djurfeldt, MSc, Bingshu E. Chen, Annette E Hay

Blood (2017) 130 (Supplement 1): 4081.

https://doi.org/10.1182/blood.V130.Suppl_1.4081.4081

Published: 2017

Journal Articles

Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Tanya Skamene, MD, Wenyu Jiang, PhD, Ralph M. Meyer, MD, Michael Crump, MD, John Kuruvilla, MD, C. Tom Kouroukis, MD MSc, FRCPC, Stefano Luminari, Stephen Couban, MD, Matthew C. Cheung, MD SM, FRCPC, David A Rizzieri, MD, Peter G Bardy, MBBS, FRACP, FRCPA, Joseph Pater, MD MSc, Marina S. Djurfeldt, MSc, Lois E. Shepherd, MD, Bingshu E Chen, PhD, Annette E Hay, MB ChB

Blood (2016) 128 (22): 690.

https://doi.org/10.1182/blood.V128.22.690.690

Published: 2016

Journal Articles

Addition of Rituximab to Salvage Chemotherapy in Aggressive CD20+ Lymphoma Prior to Autologous Stem Cell Transplant (ASCT): A Cohort Comparison from the NCIC CTG Study LY.12

Tara Baetz, MD, Bingshu E Chen, PhD, Stephen Couban, MD, C. Tom Kouroukis, MD MSc, FRCPC, Rena Buckstein, MD, John Kuruvilla, MD, Kang Howson-Jan, David Szwajcer, MD FRCPC, Massimo Federico, MD, Ralph M. Meyer, Robert Turner, MD, Marina S Djurfeldt, MSc, Annette E Hay, MB ChB, Lois Shepherd, MD, Michael Crump, MD

Blood (2014) 124 (21): 1712.

https://doi.org/10.1182/blood.V124.21.1712.1712

Published: 2014

Journal Articles

Final Analysis of a Randomized Comparison of ABVD Chemotherapy with a Strategy That Includes Radiation Therapy (RT) in Patients with Limited-Stage Hodgkin Lymphoma (HL): NCIC CTG/ECOG HD.6

Ralph M. Meyer, MD, Mary Gospodarowicz, MD, Joseph M. Connors, MD, Robert G Pearcey, MD, Woodrow A Wells, MD, Jane N. Winter, MD, Sandra J. Horning, MD, A. Rashid Dar, MD, Chaim Shustik, MD, Douglas A. Stewart, MD, Michael Crump, MD, FRCPC, Marina S Djurfeldt, MSc, Bingshu E Chen, PhD, Lois E Shepherd, M.D.

Blood (2011) 118 (21): 590.

https://doi.org/10.1182/blood.V118.21.590.590

Published: 2011

Journal Articles

Relapse Patterns and Subsequent Outcomes of Patients Treated on the NCIC CTG HD.6 (ECOG JHD06) Randomized Trial Evaluating ABVD Alone in Patients with Limited Stage Hodgkin Lymphoma (HL).

David A. Macdonald, MD, Mary K. Gospodarowicz, MD, Woodrow A. Wells, MD, Robert G. Pearcey, MD, Joseph M. Connors, MD, Jane N. Winter, MD, Sandra J. Horning, MD, Marina S. Djurfeldt, MSc, Keyue Ding, PhD, Lois E. Shepherd, MD, Ralph M. Meyer, MD

Blood (2005) 106 (11): 817.

https://doi.org/10.1182/blood.V106.11.817.817

Published: 2005

NARROW

Potential Utility of Event-Free Survival (EFS) As Surrogate Endpoint for Overall Survival (OS) in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) after Autologous Stem Cell Transplantation (ASCT): A Subgroup Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Randomized Phase III Trial

Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Comparison of Outcomes By Age of Patients with Limited Stage Hodgkin Lymphoma Treated with ABVD Alone; A Secondary Analysis of the Canadian Cancer Trial Group HD.6 Trial

Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Addition of Rituximab to Salvage Chemotherapy in Aggressive CD20+ Lymphoma Prior to Autologous Stem Cell Transplant (ASCT): A Cohort Comparison from the NCIC CTG Study LY.12

Final Analysis of a Randomized Comparison of ABVD Chemotherapy with a Strategy That Includes Radiation Therapy (RT) in Patients with Limited-Stage Hodgkin Lymphoma (HL): NCIC CTG/ECOG HD.6

Relapse Patterns and Subsequent Outcomes of Patients Treated on the NCIC CTG HD.6 (ECOG JHD06) Randomized Trial Evaluating ABVD Alone in Patients with Limited Stage Hodgkin Lymphoma (HL).

Email alerts

ASH Publications

American Society of Hematology

Potential Utility of Event-Free Survival (EFS) As Surrogate Endpoint for Overall Survival (OS) in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) after Autologous Stem Cell Transplantation (ASCT): A Subgroup Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Randomized Phase III Trial

Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Comparison of Outcomes By Age of Patients with Limited Stage Hodgkin Lymphoma Treated with ABVD Alone; A Secondary Analysis of the Canadian Cancer Trial Group HD.6 Trial

Impact of Wait Times for Autologous Stem Cell Transplantation in Patients with Aggressive Non-Hodgkin Lymphoma, a Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical Trial

Addition of Rituximab to Salvage Chemotherapy in Aggressive CD20+ Lymphoma Prior to Autologous Stem Cell Transplant (ASCT): A Cohort Comparison from the NCIC CTG Study LY.12

Final Analysis of a Randomized Comparison of ABVD Chemotherapy with a Strategy That Includes Radiation Therapy (RT) in Patients with Limited-Stage Hodgkin Lymphoma (HL): NCIC CTG/ECOG HD.6

Relapse Patterns and Subsequent Outcomes of Patients Treated on the NCIC CTG HD.6 (ECOG JHD06) Randomized Trial Evaluating ABVD Alone in Patients with Limited Stage Hodgkin Lymphoma (HL).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only